Nektar Therapeutics (NKTR) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$1.21

Estimate

-$2.04

Surprise

+40.5%

Revenue (period 2026-06-30)

$10.1M

Score today

4.2/10

Revenue source: xbrl.

Nektar Therapeutics (NKTR) reported a narrower loss than forecast — diluted EPS of -$1.21 against the -$2.04 estimate (a 40.5% beat on a still-unprofitable quarter).

• Full Transcript: Nektar Therapeutics Q2 2026 Earnings Call — benzinga, 2026-08-13
• Nektar Therapeutics Q2 EPS $(1.23) Beats $(2.00) Estimate, Sales $10.131M Miss $10.425M Estimate — benzinga, 2026-08-13

TrendMatrix currently rates NKTR Sell at 4.2/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +40.5% surprise compares with a +29.1% four-quarter average. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$75.80

Price target

$125.63

Stop

$71.02

Upside to target

+65.7%

Reward-to-risk

7.6:1

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$2.61B

P/E (fwd)

-7.0

52-week range

$33.40–$109.00

Off 52-week high

30.5%

RSI (14)

60

Volume vs avg

1.24×

Score today

4.2/10